Synthesis and Evaluation of Moxifloxacin Derivatives for Effects on Proliferation and Apoptosis of NCI-H1299 Cells

Fangmiao Yu,Zhuangwei Zhang,Wei Li,Hengqun Tian,Jun Xu,Yongzhong Bao
DOI: https://doi.org/10.1016/j.tetlet.2020.151873
IF: 2.032
2020-01-01
Tetrahedron Letters
Abstract:Eight novel moxifloxacin (MXF) derivatives 4a-h were synthesized by functional modification of the N-5-Aza ring. Their growth inhibitory activities on human non-small lung cancer cell NCI-H1299 and A549 were evaluated by the MTT colorimetric assay. Based on the half inhibitory concentration (IC50) values, we determined that compounds 4b was the most efficacious derivative (IC50 = 2.56 +/- 0.07 mu M for NCI-H1299 and IC50 = 13.69 +/- 0.70 mu M for A549, respectively) that inhibited the proliferation of NCI-H1299 cells. Of these, Compound 4b (1 - cyclopropyl - 6 - fluoro - 8 - methoxy - 4 - oxo - 7 - ((4aS,7aS) - 1 - (2 - oxo - 2 - (p - tolylamino) ethyl) hexahydro - 1H - pyrrolo [3,4-b] pyridine - 6 (2H)-yl) - 1,4 - dihydroquinoline - 3-carboxylic acid) showed good potency against the growth of NCI-H1299 cells and also selectivity on HUVEC cells (IC50 > 500 mu M). The dose-response relationship of the characteristic morphological changes of NCI-H1299 cells induced by Compound 4b was confirmed by AO/EB fluorescent staining. Furthermore, Compound 4b triggered apoptosis of NCI-H1299 in a concentration-dependent manner and arrested cells in the G0/G1 phase. These data indicate that the N-(p-tolyl) propanamide functionalized N-5-Aza ring of moxifloxacin may be a promising lead compound and candidate for the development of new agents against non-small-cell lung cancer. (C) 2020 Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?